TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03857035

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Piezosurgery group
Description: Piezosurgery technique will be examined about impacted third molar surgery.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Piezosurgery group
Description: Piezosurgery technique will be examined about impacted third molar surgery.
Study: NCT02562703

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Vagus Nerve Stimulation
Description: tVNS will be applied by the external simulator (Monarch). The stimulation will be conducted at a frequency of 120 Hz with pulse duration of 250 microseconds. The current intensity will be individually established and should be equivalent to a slight feeling of not painful paresthesia .The stimulus generates a pulse and asymmetric biphasic waveform. Electrodes (25cm2) will be placed over the mastoid process bilaterally. The study protocol will follow the rational of our previous trials with TNS.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous Vagus Nerve Stimulation
Description: tVNS will be applied by the external simulator (Monarch). The stimulation will be conducted at a frequency of 120 Hz with pulse duration of 250 microseconds. The current intensity will be individually established and should be equivalent to a slight feeling of not painful paresthesia .The stimulus generates a pulse and asymmetric biphasic waveform. Electrodes (25cm2) will be placed over the mastoid process bilaterally. The study protocol will follow the rational of our previous trials with TNS.
Study: NCT02954562

Intervention type: OTHER
Intervention: fMRI
Description: Participants will undergo two to three fMRI scans
Study: NCT04407052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Double trigger
Description: Final follicular maturation is triggered by the coadministration of GnRH-agonist (Triptorelin acetate, decapeptyl 0.2 mg, Slough, United Kingdom) and 10000 IU of HCG, 40 and 34 h prior to oocyte retrieval, respectively

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HCG trigger
Description: Final follicular maturation is triggered by a dose of 10000 IU of HCG 36 h prior to oocyte retrieval
Study: NCT02612038

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Expiratory resistance
Description: Generic expiratory resistance will be added to the patient's respiratory circuit

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham expiratory resistance
Description: Sham expiratory resistance will be added to the patient's respiratory circuit
Study: NCT02993718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: As a loading dose, 0.5 μg/kg dexmedetomidine was administered over 10 min, which was then administered continuously at a dose of 0.2-0.8 μg/kg/h. Sedation was maintained at modified observer's assessment of alertness/sedation scale 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol was infused continuously via a target-controlled infusion device, and the effect-site concentration was maintained with a range of 0.5-2.0 μg/ml. Sedation was maintained at modified observer's assessment of alertness/sedation scale 3
Study: NCT02607722

Intervention type: DRUG
Intervention: Nintedanib
Study: NCT02273531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asasantin ER, new formulation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Asasantin ER, present commercial formulation
Study: NCT02603497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP015K
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP015K
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP015K
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP015K
Description: oral
Study: NCT04474301

Intervention type: OTHER
Intervention: Survey Administration
Description: Complete survey
Study: NCT01854762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: a raltegravir-based antiretroviral regimen (AZT+3TC+Raltegravir) will be administered for intervention arm patients (AZT+3TC will be administered in a fixed combination of AZT 300mg +3TC 150 mg, BID. Raltegravir will be administered in a dosis of 1 400 mg pill BID).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir/Ritonavir
Description: The second arm (comparator)patients will use a regimen composed by AZT+3TC (same dosis/schedule of active arm)+ LPV 200mg combined with rtv 50 mg, 2 pills BID
Study: NCT04414930

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: d-amphetamine
Description: Subjects complete 30 sessions of Targeted Cognitive Training (2-3 times per week), and receive amphetamine 5 mg po 1 hour prior to each training.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects complete 30 sessions of Targeted Cognitive Training (2-3 times per week), and receive placebo po 1 hour prior to each training.
Study: NCT00708981

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multifactorial Intervention
Description: Study group will receive multifactorial intervention for advanced diabetic nephropathy:~Elements of multifactorial intervention:~1. BP control of \<130/80mmHg and renal protection with reduction of proteinuria to \<0.5g/day using therapy with ACE inhibitors and/or ARBs.~2. Tight glucose control with target of HbA1C of 7% and below using SMBG and Lantus/Apidra regimen.~3. Use of hypolipidemic therapy to achieve targets of LDL \< 70 mg/dl, HDL \> 40/50 mg/dl (M/F)and TG \< 200 mg/dl.~4. Patient enhanced self-management provided by combined diabetes-renal education curriculum.~5. Behavior and social intervention~6. Intense case management that includes close follow-up of visits, laboratory monitoring and other self-adherence behaviors carried out by clinical research coordinators.
Study: NCT02262325

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hypofractionated radiation therapy
Description: Radiation boost in week 1 (days 1-5)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study: NCT04348461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allogeneic and expanded adipose tissue-derived mesenchymal stromal cells
Description: Two serial doses of 1.5 million adipose-tissue derived mesenchymal stem cells per kg
Study: NCT02262325

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy
Description: Undergo 3-dimensional conformal radiation therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04134936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafasitamab
Description: Six 21-day cycles of tafasitamab (12 mg/kg intravenously, on Day 1, 8 and 15) in addition to R-CHOP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafasitamab plus lenalidomide
Description: Six 21-day cycles of tafasitamab (12 mg/kg intravenously, on Day 1, 8 and 15) plus lenalidomide (starting dose 25 mg orally, on Day 1-10) in addition to R-CHOP
Study: NCT02787460

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Text Messages
Study: NCT00130676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: daily for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: matching placebo
Description: daily for 7 days
Study: NCT01785407

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Iron Supplement (Ferrous Sulfate Dried)
Description: Iron supplements of varying concentration will be administered to the four groups in the study. Iron bioavailability from the supplements will be assessed.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Iron Supplement (Ferrous Sulfate Dried)
Description: Iron supplements of varying concentration will be administered to the four groups in the study. Iron bioavailability from the supplements will be assessed.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Iron Supplement (Ferrous Sulfate Dried)
Description: Iron supplements of varying concentration will be administered to the four groups in the study. Iron bioavailability from the supplements will be assessed.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Iron Supplement (Ferrous Sulfate Dried)
Description: Iron supplements of varying concentration will be administered to the four groups in the study. Iron bioavailability from the supplements will be assessed.
Study: NCT04406610

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GD2 CAR-T immunotherapy
Description: Antigen-specific T cell therapy
Study: NCT00752037

Intervention type: DRUG
Group type: OTHER
Intervention: lopinavir/ritonavir and raltegravir
Description: lopinavir/ritonavir 400/100 mg po b.id. in combination with raltegravir 400 mg po b.i.d.
Study: NCT03241615

Intervention type: OTHER
Intervention: Dysphagia evaluation
Description: Dysphagia evaluation is performed in a clinical setting by an eating assessment tool. Swallowing related quality of life is also assessed.
Study: NCT00417287

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PX-12
Description: 3 hour intravenous infusion as a dose of either 54 mg/m2 or 128 mg/m2 daily for 5 days every three weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PX-12
Description: 3 hour intravenous infusion as a dose of either 54 mg/m2 or 128 mg/m2 daily for 5 days every three weeks.
Study: NCT01641510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: Loading with prasugrel 30 mg followed by daily administration of prasugrel 5 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Loading with clopidogrel 600 mg followed by daily administration of clopidogrel 75 mg
Study: NCT02370342

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robot-Assisted Laparoscopic Surgery
Description: Undergo robot-assisted laparoscopic HIFU ablation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High-Intensity Focused Ultrasound Ablation
Description: Undergo robot-assisted laparoscopic HIFU ablation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Laparoscopic Surgery
Description: Undergo laparoscopic partial nephrectomy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sonatherm 600i Ultrasonic Lesion Generating System
Description: Device used for high-intensity focused ultrasound ablation
Study: NCT01040026

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment with in vitro expanded haploidentical NK cells
Description: 10 expanded NK-DLI will be applied at fixed intervals and to each patient within 30 days (3 applications per week, Mo/We/Fr) starting with increasing CD56+CD3- NK cell doses at 3 dose levels (1.5x10e6/kg, 1.5x10e7/kg and 1x10e8/kg) and, if safe, continuing with maximally 7 doses of 1x10e8/kg. Maximal cumulative T-cell dose is fixed at \<1x10e5/kg
Study: NCT02793050

Intervention type: DRUG
Intervention: Trabectedin
Description: Collection of data on the clinical use of Trabectedin
Study: NCT00935298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: The genotyping of gene CYP3A5 will be carried out in the 4-7days before renal transplantation. After transplantation, the patients will be treated by MMF, corticosteroids and tacrolimus at a dosage adapted to their genotype(CYP3A5\*1/\*1 type and CYP3A5\*1/\*3 type administer 0.15mg/kg/d，CYP3A5\*3/\*3 type administer 0.08mg/kg/d).
Study: NCT00622206

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ritonavir and saquinavir
Description: saquinavir/ritonavir 1500/100 mg or 1500/50 mg Twenty HIV-infected volunteers on stable doses of SQV/RTV 1500/100 mg OD for at least 3 months with an NRTI backbone and undetectable viral load will participate. After collecting samples for a full PK curve subjects will be switched to SQV/RTV 1500 /50 mg OD + 2NRTIs for 1 week before repeating the PK assessment. Blood samples will be drawn at T 0, 1, 2, 4, 6, 8, 10, 12 and 24 hours post ingestion. Consecutively to the assessment, subjects will return to SQV/RTV 1500/100 mg OD dosage.
Study: NCT04248452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO
Study: NCT02438657

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: median nerve block
Study: NCT04248452

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Given PO
Study: NCT03588871

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dental bleaching with PaintOn Plus VivaStyle
Description: Procedure of tooth bleaching using products with 6% hydrogen peroxide or its equivalent, specifically the PaintOn Plus Vivastyle 6% HP (Ivoclar Vivadent)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dental Bleaching impact in quality of life with PaintOn Plus Vivastyle
Description: Evaluation of oral quality of life after dental bleaching treatment with PaintOn Plus Vivastyle 6% HP (Ivoclar Vivadent) using an oral quality of life measuring questionnaire, specifically the Oral Health Impact Profile-14

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dental bleaching with Opalescence GO
Description: Procedure of tooth bleaching using products with 6% hydrogen peroxide or its equivalent, specifically the Opalescence GO 6% HP (Ultradent)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dental Bleaching impact in quality of life with Opalescence GO
Description: Evaluation of oral quality of life after dental bleaching treatment with Opalescence GO 6% HP (Ultradent) using an oral quality of life measuring questionnaire, specifically the Oral Health Impact Profile-14

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dental bleaching with Opalescence PF
Description: Procedure of tooth bleaching using products with 6% hydrogen peroxide or its equivalent, specifically the Opalescence PF 16% CP (Ultradent)
Study: NCT04248452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin Calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study: NCT01854775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E/C/F/TAF
Description: Tablets administered orally with food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E/C/F/TAF
Description: Tablets administered orally with food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E/C/F/TAF
Description: Tablets administered orally with food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E/C/F/TAF (Low Dose)
Description: 90/90/120/6 mg STR administered once daily orally with food.
Study: NCT04500821

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activator LFD-2100
Description: LipiFlow treatment with the Activators LFD-2100 will be performed on both eyes with MGD
Study: NCT04464538

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WALC-R
Description: Initial group education session and individualized coaching (remote)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Information leaflet
Description: Participants in the control group will complete baseline measures, and then they will receive written information on the benefits of increasing activity levels. This advice will be given in accordance with NHS guide on physical health.
Study: NCT02392728

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Immersive Virtual Reality (VR)
Description: Patients in this group will experience the virtual content (e.g., natural scenes) through a Head-Mounted-Display, simulating movement by manipulating a gesture controller. Following a resting period the patients will then experience the guided imagery session (e.g. visual images of pleasant scenery)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immersive Virtual Reality (VR)
Description: Patients in this group will experience the virtual content (e.g., natural scenes) through a Head-Mounted-Display, simulating movement by manipulating a gesture controller. Following a resting period the patients will then experience the guided imagery session (e.g. visual images of pleasant scenery)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Guided Imagery
Description: Patients in this group will experience the guided imagery (e.g. visual images of pleasant scenery). Following a resting period the patients will then experience the virtual content (e.g., natural scenes) through a Head-Mounted-Display, simulating movement by manipulating a gesture controller

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Imagery
Description: Patients in this group will experience the guided imagery (e.g. visual images of pleasant scenery). Following a resting period the patients will then experience the virtual content (e.g., natural scenes) through a Head-Mounted-Display, simulating movement by manipulating a gesture controller
Study: NCT03014505

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FMT
Description: Fecal Microbiota Transplantation and the traditional treatments for Decompensated Cirrhosis in part 1

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional treatments
Description: traditional treatments for Decompensated Cirrhosis in part 2
Study: NCT02505074

Intervention type: PROCEDURE
Intervention: Valve replacement with the Melody valve
Description: This study will only review patients who have had the Melody valve surgically inserted into the Mitral and/or Tricuspid positions. We will not be reviewing any other intervention type.

Intervention type: PROCEDURE
Intervention: Valve replacement with the Melody valve
Description: This study will only review patients who have had the Melody valve surgically inserted into the Mitral and/or Tricuspid positions. We will not be reviewing any other intervention type.
Study: NCT04787341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: regorafenib administered until progression, unacceptable toxicity or patient's refusal followed after progression by panitumumab until further progression, unacceptable toxicity or patient's refusal in RAS and BRAF wt mCRC patients with the following characteristics:~1. previous treatment with, or not considered candidates for, fluoropyrimidine, oxaliplatin, irinotecan and anti-angiogenic agent (bevacizumab or aflibercept);~2. RECIST response or stable disease lasting at least 6 months to a previous first-line anti-EGFR-based treatment;~3. RAS and BRAF wt ct-DNA at the time of screening.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Panitumumab
Description: panitumumab administered until progression, unacceptable toxicity or patient's refusal followed after progression by regorafenib until further progression, unacceptable toxicity or patient's refusal in RAS and BRAF wt mCRC patients with the following characteristics:~1. previous treatment with, or not considered candidates for, fluoropyrimidine, oxaliplatin, irinotecan and anti-angiogenic agent (bevacizumab or aflibercept);~2. RECIST response or stable disease lasting at least 6 months to a previous first-line anti-EGFR-based treatment;~3. RAS and BRAF wt ct-DNA at the time of screening.
Study: NCT04180462

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Practice Facilitation
Description: Practice facilitation to support quality improvement methods to effect practice change to develop a sustainable HPV vaccine delivery system.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: An educational video to increase the provider's knowledge about guideline recommendations and patient and practice benefits of vaccination by age 13.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Audit and Feedback
Description: Audit and feedback of vaccine coverage to increase motivation to engage in practice change.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Communication Strategy
Description: A communication strategy to improve the provider's communication skills and their self-efficacy to address parental hesitation.
Study: NCT04018417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amphotericin B
Description: Drug concentration: 0.255 μg/mL
Study: NCT04018092

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active NIR-PBM
Description: See Experimental arm for description.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham NIR-PBM
Description: See Sham Comparator arm for description.
Study: NCT01363479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral palonosetron

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: I.V. palonosetron
Study: NCT03588871

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dental Bleaching impact in quality of life with Opalescence PF
Description: Evaluation of oral quality of life after dental bleaching treatment with Opalescence PF 16% CP (Ultradent) using an oral quality of life measuring questionnaire, specifically the Oral Health Impact Profile-14